Poorni M. Manohar, MD

Research Reports

Bone-Modifying Agent Utilization: An Analysis in Patients With Metastatic Cancer and Bone Involvement at an NCI-Designated Cancer Center

04/12/2023

Julie Gralow , MD, FACP, FASCO;

Micah Tratt ;

Keith D. Eaton , MD, PhD;

Poorni M. Manohar , MD;

Kyle E. Bastys ;

Manohar et al investigate the cost of utilizing bone-modifying agents in the treatment of patients with metastatic cancer and bone involvement at a National Cancer Institute–designated cancer center.

Manohar et al investigate the...

04/12/2023

Journal of Clinical Pathways

Research Reports

Potential Cost Effectiveness of FES-PET to Determine Estrogen Receptor Status in Metastatic Breast Cancer in the United States

10/20/2021

Hannah M. Linden , MD;

Poorni M. Manohar , MD;

Josh A. Roth , PhD, MHA;

Poorni M. Manohar, MD, et al assessed the potential value of 18-F 16 alpha-fluoroestradiol positron emission tomography (FES-PET) vs biopsy to determine estrogen receptor status and guide therapy selection in metastatic breast cancer.

Poorni M. Manohar, MD, et al...

10/20/2021

Journal of Clinical Pathways